Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPENASDAQ:BLCMNYSE:CPHINASDAQ:INM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.02$0.00▼$0.45$3K4.92609 shs1 shsBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsCPHIChina Pharma$1.83+5.2%$1.87$1.20▼$3.35$5.96M0.7774,788 shs36,466 shsINMInMed Pharmaceuticals$3.38-2.3%$2.86$1.72▼$15.70$4.08M0.171.01 million shs250,562 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%-10.00%+350.00%-98.07%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CPHIChina Pharma0.00%+4.40%-3.89%-93.35%-92.74%INMInMed Pharmaceuticals0.00%+35.74%+37.96%+64.08%-35.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio Pharmaceuticals0.1469 of 5 stars0.03.00.00.00.00.00.6BLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACPHIChina Pharma0.1077 of 5 stars0.03.00.00.00.00.80.0INMInMed Pharmaceuticals1.0086 of 5 stars0.05.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ABLCMBellicum Pharmaceuticals 0.00N/AN/AN/ACPHIChina Pharma 0.00N/AN/AN/AINMInMed Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ABLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CPHIChina Pharma$4.30M1.39N/AN/A$0.70 per share2.61INMInMed Pharmaceuticals$4.60M0.89N/AN/A$20.64 per share0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/ABLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/AINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-168.87%-107.93%-82.97%N/ALatest CPHI, BLCM, AMPE, and INM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/AN/AN/ABLCMBellicum PharmaceuticalsN/A3.043.04CPHIChina Pharma0.220.790.26INMInMed Pharmaceuticals0.063.493.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%BLCMBellicum Pharmaceuticals4.93%CPHIChina PharmaN/AINMInMed Pharmaceuticals20.12%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%BLCMBellicum Pharmaceuticals10.30%CPHIChina Pharma17.32%INMInMed Pharmaceuticals1.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableINMInMed Pharmaceuticals101.21 million1.19 millionNot OptionableCPHI, BLCM, AMPE, and INM HeadlinesRecent News About These CompaniesInMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq RulesJune 27 at 7:00 AM | newsfilecorp.comNPromising Penny Stocks To Consider - June 24thJune 26 at 4:07 AM | americanbankingnews.comCannabis Stocks To Watch Today - June 24thJune 26 at 2:03 AM | americanbankingnews.comInMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 25, 2025 | newsfilecorp.comNInMed stock soars after promising Alzheimer’s drug preclinical resultsJune 24, 2025 | in.investing.comInMed Shares Jump After Positive Preclinical Data for INM-901June 24, 2025 | marketwatch.comInMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo StudyJune 24, 2025 | newsfilecorp.comNInMed Pharmaceuticals: InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes ...June 14, 2025 | finanznachrichten.deInMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPAJune 13, 2025 | newsfilecorp.comNNew CB1 and CB2 receptor modulators disclosed in Inmed patentMay 31, 2025 | bioworld.comBInMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 12, 2025 | newsfilecorp.comNInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comInMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | newsfilecorp.comNInMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | newsfilecorp.comNInMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | finanznachrichten.deInMed advances AMD treatment with promising IVT drug formulationFebruary 3, 2025 | msn.comInMed Pharmaceuticals announces INM-089 IVT formulation as drug candidateFebruary 3, 2025 | markets.businessinsider.comInMed Advances INM-089 for Dry AMD Treatment with New Intravitreal FormulationFebruary 3, 2025 | tipranks.comInMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPHI, BLCM, AMPE, and INM Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0027 0.00 (0.00%) As of 06/27/2025Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Bellicum Pharmaceuticals NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.China Pharma NYSE:CPHI$1.83 +0.09 (+5.18%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$1.81 -0.02 (-0.88%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.InMed Pharmaceuticals NASDAQ:INM$3.38 -0.08 (-2.31%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.32 -0.06 (-1.75%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
